The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Fixed-duration SC mosunetuzumab in older patients with previously untreated DLBCL: MorningSun trial
Jeff Sharman, MD, Sarah Cannon Research Institute at Willamette Valley Cancer Institute & Research Center, Eugene, OR, discusses the interim results from a cohort of the Phase II MorningSun study (NCT05207670), which evaluated the efficacy and safety of fixed-duration subcutaneous (SC) mosunetuzumab monotherapy in older or unfit patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Dr Sharman highlights that the study demonstrated encouraging response rates and a manageable safety profile, with low rates of cytokine release syndrome (CRS) and no reported cases of immune effector cell-associated neurotoxicity syndrome (ICANS). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
